rising revenue and wide moats , page-8

Apparently the directors are pretty keen on dividends, understandable as they are only on modest salaries but have substantial shareholdings in the company. I believe the situation as it stands at present is that a large percentage of profits will go out as dividends with omly modest amounts required for R & D.
One other need for funds could be an add-on acquisition, the last newsletter seemed to indicate this could be a possibility in the future.

As for what franking credits will be available I can't help much, it probably would depend on what transfer pricing they do. Bit of a (pleasant?)headache for the CFO, say if product is manufactured here in Australia and sold into Asia what are the rules? Also with US sales, most likely the product there will be manufactured by Scantbodies and sold by Cellestis Inc, the US subsidiary.

Any beancounters with international experience care to illuminate us all please?

regards, EB